Tempus AI, Inc. (BCBA:TEMD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 12.33T -7.6% |
| Revenue (ttm) | 1.88T +69.8% |
| Net Income | -418.47B |
| EPS | -2,380.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.850 |
| Previous Close | 4.080 |
| Day's Range | 3.850 - 3.850 |
| 52-Week Range | 3.780 - 6.035 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Tempus AI announces national launch of OneOme pharmacogenomics testing
Tempus AI (TEM) announced the national launch of its OneOme pharmacogenomics testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. ...
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneO...
Personalis price target raised to $16.25 from $11 at BTIG
BTIG raised the firm’s price target on Personalis (PSNL) to $16.25 from $11 and keeps a Buy rating on the shares after Tempus AI (TEM) said it will acquire Personalis…
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a “Market Misread”
Tempus AI ($TEM) stock fell about 8% on Monday after the health technology company said it will acquire biotechnology company Personalis ($PSNL) in an all-stock deal valued at $1.7 billion. The…
Morgan Stanley sees strategic logic in Personalis deal despite financial hurdles
Morgan Stanley notes that Tempus AI (TEM) announced a definitive agreement to acquire Personalis (PSNL) for $16.25 per share, with the deal expected to close in late 2026 or early…
AI Daily: Tempus AI to acquire Personalis at enterprise value of $1.5B
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly. PERSONALIS…
Midday Fly By: Domino’s reports mixed Q2, Tempus AI to acquire Personalis
The major averages were mixed near noon as stocks look to rebound from last week’s technology-led selloff. Attention is turning to a week of megacap earnings that could determine whether…
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.
Personalis downgraded to Hold from Buy at Lake Street
Lake Street analyst Thomas Flaten downgraded Personalis (PSNL) to Hold from Buy with a price target of $16.25, up from $11, after Tempus AI (TEM) announced a definitive agreement to…
Tempus AI Transcript: M&A announcement
The acquisition will combine complementary MRD assay portfolios, accelerate commercial adoption, and enhance data-driven insights for biopharma clients. The $1.5B all-stock deal is timed as Personalis' financials improve, with integration and expanded reimbursement expected to drive growth and profitability by 2027.
Tempus AI Press release: M&A announcement
Tempus AI issued a press release on July 20, 2026, disclosing material business information to investors.
Tempus AI Slides: M&A announcement
Tempus AI has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Tempus to acquire Personalis for $1.5 billion
Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm's oncology portfolio.
Tempus AI to acquire Personalis for $16.25 per share
08:31 EDT Tempus AI (TEM) to acquire Personalis (PSNL) for $16.25 per share
Tempus AI to acquire Personalis for $16.25 per share
Tempus AI (TEM) entered into a definitive agreement to acquire Personalis (PSNL). The acquisition will expand Tempus’ capabilities in minimal residual disease and enhance its ability to support patien...
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a defi...
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medi...
Tempus AI price target raised to $65 from $60 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Tempus AI (TEM) to $65 from $60 and keeps a Buy rating on the shares. The firm is updating its…
Tempus AI price target raised to $71 from $68 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Tempus AI (TEM) to $71 from $68 and keeps a Buy rating on the shares. The firm adjusted targets…
Tempus to Report Second Quarter 2026 Financial Results on July 30
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second ...
Tempus AI initiated with a Hold at Freedom Capital
Freedom Capital analyst Gene Mannheimer initiated coverage of Tempus AI (TEM) with a Hold rating and $59 price target Healthcare AI is one of the fastest-growing technology segments, says the…
Tempus AI announces research collaboration with Angiosarcoma Awareness
Tempus AI (TEM) announced a research collaboration with Angiosarcoma Awareness to accelerate data-driven research in angiosarcoma. The collaboration will leverage Tempus’ robust datasets and compute a...
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with A...
Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms
Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.
Tempus AI announces publication of multi-center validation of software
Tempus AI (TEM) announced publication of a multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrilla...